Human SLAM/CD150 PE-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: SLAM/CD150

Signaling Lymphocytic Activation Molecule (SLAM), also known as SLAMF1 and CD150, was the first identified family member of type I transmembrane (TM) lymphocyte activating receptors. SLAM homotypic adhesion bidirectionally stimulates T and B cells. SLAM is also expressed by hematopoietic stem cells, dendritic cells and platelets and is a T cell measles virus receptor. The 70 kDa glycoprotein contains a 216 amino acid (aa) extracellular domain (ECD) with one C2 type and one V type Ig-like domain, a 20 aa TM sequence and a 76 aa SH2-binding cytoplasmic domain. One splice variant has a shorter cytoplasmic tail and another lacks the TM sequence and is secreted. Human and mouse SLAM ECD share 60% aa identity.

Product Datasheets

Related Research Areas

• B Cell Activation
• Co-stimulatory and Co-inhibitory Molecules
• Co-stimulatory Molecules Associated with Tfh Cells
• Dendritic Cell Co-stimulatory Molecules
• Dendritic Cell ITIM/ITAM Immunoreceptors
• Endothelial Cell Markers
• Hematopoietic Stem Cell Markers
• ITIM/ITAM Immunoreceptors and Related Molecules
• Lymphoma
• Macrophage Activation Markers
• Megakaryocytes
• Monocyte Markers
• Natural Killer T (NKT) Cells
• Platelet Immune Receptors
• Regulatory T Cells (Tregs)